NLRP3 and intervertebral disk degenerative disorder: Targeting M1 macrophages could reduce chronic inflammation and tissue destruction, potentially slowing the progression of IDD. Metabolic reprogramming and combined inhibition of multiple pathways (NF-κB and NLRP3) may offer more comprehensive therapeutic effects.